Mesoblast (MSB)

Shares / Stock Code


Stock Exchange / Sharemarket


Mesoblast Limited (MSB) is a biotechnology company committed to the treatments for orthopaedic conditions, including the commercialisation of adult stem cell technology aimed at the regeneration and repair of bone and cartilage.

MSB was listed on the Australian stockmarket (ASX) in December 2004. MSB has also acquired an interest in Angioblast Systems Inc, an American company developing the platform of adult Mesenchymal Precursor Cell technology for the treatment of cardiovascular diseases, including repair and generation of blood vessels and heart muscle. The company completed a capital raising of $15 million in July 2006, to fund Phase II Clinical Trials in the United States.

The company holds the exclusive rights for a series of patents and technologies that have been developed over more than 10 years which relate to identification, extraction and culture of adult Mesenchymal Precursor Cells (MPCs). MSB and an American company, Angioblast, will jointly fund and progress the core MPC technology.

Major customers include patients with bone and joint diseases, including adult stem cell therapy for bone fractures and spinal disease, and for regeneration of damaged joint cartilage and intervertebral discs. Competitors consist of other medical companies involved in adult stem cell therapy.

Mesoblast is developing an allogeneic or off-the-shelf cell product, called NeoFuse, to generate bony spinal fusion. In August 2009, the United States Food and Drug Administration cleared a Phase II clinical trial of its allogeneic adult stem cells for use in minimally invasive lumbar spinal fusion surgery. The 24-patient trial, based at multiple United States sites, is comparing the effectiveness and safety of two low doses, NeoFuse with autograft in minimally invasive surgery for fusion of the lumbar spine

Mesoblast (MSB) Products and Services

  • A biotechnology company in the area of adult stem cell technology.

Mesoblast (MSB) Locations and Subsidiaries

Mesoblast Head Office
Level 39, 55 Collins Street, MELBOURNE,
Phone: (03) 9639 6036
Fax: (03) 9639 6030

Mesoblast (MSB) Share Price

Submitted by ASX Listed Company on 13 May, 2010 - 18:32